2019BSH最佳实践指南_原发性纵膈B细胞淋巴瘤的管理.pdfVIP

guideline The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper Kate Cwynarski,1 Maria A. V. Marzolini,1 Sally F. Barrington,2 George Follows,3 Timothy Illidge,4 Simon Stern,5 and Andrew Davies6, on behalf of the British Society for Haematology Guidelines 1Department of Haematology, University College London Hospitals NHS Foundation Trust, 2King’s College London and Guy’s and St Thomas’ PET Centre, School of Biomedical Engineering and Imaging Sciences, King’s College London, King’s Health Partners, London, 3Department of Haematology, Addenbrooke’s Hospital, Cambridge, 4Department of Clinical Oncology, Christie Hospital, Manchester, 5Department of Haematology, St Helier Hospital, Carshalton, and 6Department of Medical Oncology, Southampton General Hospital, Southampton, UK Keywords: lymphoid malignancies, lymphomas, malig- Lymphoma Association; this organisation does not necessar- nant haematology, primary mediastinal B cell lymphoma. ily approve or endorse the contents. Introduction Methodology Primary mediastinal B-cell lymphoma (PMBCL) represents This Good Practice Paper was compiled according to the 2–4% of non-Hodgkin lymphomas and, whilst previously con- British Society for Haematology (BSH) process at http:// sidered to be a subtype of diffuse large B-cell lymphoma .uk/guidelines. The BSH produces Good Prac- (DLBCL), gene expression profiling data has shown it to be a tice Papers to recommend good practice in areas where there separate clinicopathological entity with evidence of an overlap is a limited evidence base but for which a degree of consen- wi